There are currently 293 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
PYLARIFY® PET/CT or PET/MRI in Men with Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510
Recruiting
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +13 locations
Conditions: Prostate Cancer
Register for Updates
PSMA-PET to Guide Prostatectomy
NCT05381103
Recruiting
In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
01/29/2025
Locations: Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05628363
Recruiting
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Cancer of the Prostate
Register for Updates
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT06171139
Recruiting
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, San Francisco, California
Conditions: Prostate Cancer, Prostate Cancer Metastatic
Register for Updates
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631
Recruiting
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Gender:
MALE
Ages:
45 years and above
Trial Updated:
01/29/2025
Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia +53 locations
Conditions: Prostate Cancer, Cardiovascular Disease
Register for Updates
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT05435495
Recruiting
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, Los Angeles, Los Angeles, California +2 locations
Conditions: Prostate Cancer
Register for Updates
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
NCT05926102
Recruiting
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might he... Read More
Gender:
MALE
Ages:
Between 55 years and 69 years
Trial Updated:
01/29/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
Hypofractionated WPPT With HDR Boost
NCT06591819
Recruiting
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/28/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan +3 locations
Conditions: Prostate Cancer
Register for Updates
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT05586360
Recruiting
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized prostate cancer electing to receive prostatectomy for their care. Half the men will be randomized to receive statins for 8 weeks prior to their surgery, while the other half will receive standard of care.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina
Conditions: Prostate Cancer
Register for Updates
CYTALUX™for the Intraoperative Imaging of Prostate Cancer
NCT06434909
Recruiting
This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana +2 locations
Conditions: Prostate Cancer
Register for Updates
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
NCT04997018
Recruiting
One of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy). SBRT delivers higher than standard doses of radiation over a lower number of treatment sessions. However, there is a 20% chance that intermediate-risk prostate cancer will come back after this treatment. The purpose of this study is to find out whether giving an even higher dose (a "boost" dose) of radiation directly to the main tumor and the... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Victoria Brennan, Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates